Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 21, Issue 8, 2015, Pages 419-425

  Salaffi, Fausto ^a   Carotti, Marina ^a   Di Carlo, Marco ^a   Farah, Sonia ^a   Gutierrez, Marwin ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b National Rehabilitation Institute   (Mexico)

Author keywords

Adherence; Anti TNF; Health technology; Nonadherence; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BIOLOGICAL THERAPY; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DOCTOR PATIENT RELATION; FEMALE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORISKY MEDICATION ADHERENCE SCALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SENESCENCE; TREATMENT REFUSAL; TREATMENT RESPONSE; AGE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; METABOLISM; PATIENT ACUITY; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION;

AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COMORBIDITY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACUITY; PHYSICIAN-PATIENT RELATIONS; SURVEYS AND QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948704449     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000320     Document Type: Article

References (50)

1. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-528.
2. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73:3-5.
3. Smolen JS, LandewéR, Breedveld FC,etal. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
4. Bykerk V, Emery P. Delay in receiving rheumatology care leads to long-term harm. Arthritis Rheum. 2010;62:3519-3521.
5. Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford). 2003;42:6-13.
6. Contreras-Yáñez I, Ponce De León S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010;340:282-290.
7. Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59:1519-1526.
8. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36:2171-2177.
9. Galo JS, Mehat P, Rai SK, et al. What are the effects of medication adherence interventions in rheumatic diseases: a systematic review [published online ahead of print February 9, 2015]. Ann Rheum Dis. 2015.
10. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337-351.
11. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force [published online ahead of print May 12, 2015]. Ann Rheum Dis. 2015.
12. Pasma A, van 't Spijker A, Luime JJ, et al. Facilitators and barriers to adherence in the initiation phase of disease-modifying antirheumatic drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment. J Rheumatol. 2015;42:379-385.
13. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
14. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care. 1986;24:67-74.
15. Kingsbury SR, Gross HJ, Isherwood G, et al. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology (Oxford). 2014;53:937-947.
16. King D, Knapp M, Patel A, et al. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol Psychiatr Sci. 2014;23:61-70.
17. Stucki G, Liang MH, Stucki S, et al. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum. 1995;38:795-798.
18. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7: R796-R806.
19. Salaffi F, Cimmino MA, Leardini G, et al. Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol. 2009;27:552-559.
20. Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46:975-979.
21. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
22. van der Heijde D, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford). 1999;38: 941-947.
23. Salaffi F, Carotti M. Interobserver variation in quantitative analysis of hand radiographs in rheumatoid arthritis: comparison of 3 different reading procedures. J Rheumatol. 1997;24:2055-2056.
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-497.
25. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
26. Patient Adherence: The Next Frontier in Patient Care - Capgemini. Available at: https://www.capgemini.com//patient-adherence-the-next-frontier-in-patient-care. Accessed May 26, 2011.
27. Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91-99.
28. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:3046-3054.
29. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in Southern Sweden. Ann Rheum Dis. 2004;63:4-10.
30. Farahani P, Levine M, Gaebel K, et al. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2006;33: 665-670.
31. Contreras-Yáñez I, Cabiedes J, Villa AR, et al. Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748-751.
32. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, et al. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11:R26.
33. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396-402.
34. Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Healthcare. Baltimore, MD: Johns Hopkins University Press; 1979:1-7.
35. Tkacz J, Ellis L, Bolge SC, et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther. 2014;36:737-747.
36. Waimann CA, Marengo MF, de Achaval S, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum. 2013;65:1421-1429.
37. Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54:494-499.
38. Deyo RA. Compliance with therapeutic regimens in arthritis: issues, current status, and a future agenda. Semin Arthritis Rheum. 1982;122:233-244.
39. Brus HL, van de Laar MA, Taal E, et al. Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis. 1998;57:146-151.
40. Owen SG, Friesen WT, Roberts MS, et al. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol. 1985;24:313-320.
41. López-González R, León L, Loza E, et al. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol. 2015;33:559-569.
42. Pasma A, van't Spijker A, Hazes JM, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43:18-28.
43. Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62:857-864.
44. da Silva JA, Ramiro S, Pedro S, et al. Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatol Port. 2010;35:192-199.
45. Curtis JR, Hobar C, Hansbrough K. Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin. 2011;27:71-78.
46. Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol. 2009;36:2178-2182.
47. Nicolau G, Yogui MM, Vallochi TL, et al. Sources ofdiscrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol. 2004;31:1293-1296.
48. Aletaha D, Machold KP, Nell VP, et al. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Rheumatology (Oxford). 2006;45:1133-1139.
49. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum. 2002;47:391-397.
50. Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence. 2015;9:121-131.